How to Source Propranolol Extended-Release Capsules for Pharmaceutical Formulation
Propranolol Extended-Release Capsules (Extended-Release Capsules, 60 mg, 80 mg, 120 mg, 160 mg) is classified under Antipsychotropic Drugs. It is therapeutically aligned with reference brands such as Inderal LA®. This guide highlights key sourcing factors buyers should consider when procuring high-quality Propranolol Extended-Release Capsules for formulation, R&D, or bulk manufacturing.
Product Overview:
Propranolol is a non-selective beta-adrenergic blocker that inhibits β1 and β2 receptors, reducing heart rate, cardiac output, and blood pressure. It decreases sympathetic nervous system activity, making it effective for hypertension, angina pectoris, arrhythmias, migraine prophylaxis, and essential tremor. The extended-release (ER) capsules provide a steady release over 24 hours, improving compliance and maintaining consistent blood levels. Propranolol ER is also used off-label for performance anxiety and PTSD symptoms.
Propranolol Extended-Release (ER) capsules are FDA-approved in the U.S. for treating hypertension, a...
Propranolol Extended-Release Capsules API – ideal for compliant pharmaceutical formulation.
Quick Insight: Over 60% of formulation delays are linked to poor API sourcing. A well-planned sourcing strategy can reduce risk and accelerate market entry.
1. Regulatory Compliance & Documentation
Ensure suppliers provide:
- ✔ Valid DMF (Drug Master File)
- ✔ COA (Certificate of Analysis) for each batch
- ✔ GMP, ISO, or ICH Q7 compliance certificates
2. Purity, Grade & Specification Matching
Propranolol Extended-Release Capsules must meet exact grade and purity for your dosage form:
- ✔ USP / EP / JP grade verification
- ✔ Particle size distribution check
- ✔ Residual solvent and heavy metal limits
3. Supplier Reliability & Audit History
- ✔ Positive past audit reports
- ✔ Pharma client references
- ✔ Years of proven API manufacturing experience
4. Commercial Terms: Pricing, MOQ & Flexibility
- ✔ Transparent pricing
- ✔ Pilot batch MOQ flexibility
- ✔ Volume-based discounts
5. Lead Time, Inventory & Logistics
Typical lead time for Propranolol Extended-Release Capsules is 4–6 weeks.
- ✔ Emergency dispatch options
- ✔ Regional warehousing
- ✔ Special storage if needed
6. Formulation Support
- ✔ Technical datasheets
- ✔ Sample availability
- ✔ Stability study support
Pro Tip: Engage supplier formulation experts early — it can improve bioavailability and cut development time.
Conclusion
Sourcing Propranolol Extended-Release Capsules is more than procurement—it’s a strategic partnership. With its extended-release capsules form and 60 mg, 80 mg, 120 mg, 160 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.
Next Step: Get expert assistance in sourcing Propranolol Extended-Release Capsules.
Request a Quote
Frequently Asked Questions For Sourcing of Propranolol Extended-Release Capsules
What is the typical lead time for Propranolol Extended-Release Capsules?
Lead times range from 4–6 weeks depending on supplier and region.
Is Propranolol Extended-Release Capsules available in multiple grades?
Yes — common grades include USP, EP, and JP. Verify grade suitability for your dosage form before purchase.
Does Propranolol Extended-Release Capsules require special storage?
It should be stored in a cool, dry place away from direct sunlight.
Is a Drug Master File (DMF) available for Propranolol Extended-Release Capsules?
Yes, a DMF is available for regulated markets upon request. It includes detailed quality, manufacturing, and stability data.
Can I request samples or a pilot batch of Propranolol Extended-Release Capsules?
Yes — pilot batches or samples can be arranged for R&D, stability studies, or formulation trials. MOQ may vary based on region and regulatory scope.
What compliance certificates are available for Propranolol Extended-Release Capsules?
Available documentation may include GMP, ISO 9001, ISO 14001, and ICH Q7 certificates, along with CoA, TDS, and stability data.
Is Propranolol Extended-Release Capsules suitable for regulated markets like US/EU?
Yes — compliant with EU/US/WHO GMP standards and available with regulatory support documentation for filings.
Can Propranolol Extended-Release Capsules be used in fixed-dose combinations?
Yes — many formulations support inclusion in FDCs. Compatibility studies and formulation consultation are available on request.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our
Privacy Policy.